

Optimal glycemic control improves outcomes of chronic heart failure

L Wang, N Owen

Citation

L Wang, N Owen. *Optimal glycemic control improves outcomes of chronic heart failure*. The Internet Journal of Cardiovascular Research. 2006 Volume 4 Number 2.

Abstract

There is a high prevalence of heart failure in patients with diabetes mellitus due to hyperglycemia-induced metabolic disturbances and remodeling of myocardium, as well as increased incidence of ischemic cardiomyopathy. Patients with heart failure and concurrent diabetes have an increased mortality and hospital readmission than those without diabetes. Little is known about the impact of diabetes control on the clinical outcomes of heart failure. It is likely that optimal control of diabetes with insulin or other hypoglycemic agents restores myocardial metabolic imbalance and reduces mortality and hospital readmission in heart failure.

INTRODUCTION

Previous studies have suggested that the prevalence of heart failure is several times higher in diabetic patients than in age-matched control subjects (1, 2). Recent clinical studies have also demonstrated that diabetes mellitus has significant impact of on prognosis in patients with heart failure. Patients with diabetes and heart failure have a higher mortality and hospitalization rates than patients with heart failure but no diabetes (3,4,5,6,7). The increased risk for adverse cardiovascular outcomes seems to occur mainly in diabetic and heart failure patients who had developed ischemic cardiomyopathy (4). In contrast, in patients with nonischemic aetiology, diabetes was not a predictor for all-cause death or cardiovascular death, or even associated with a decrease in cardiovascular mortality (4).

Given the significant negative impact of diabetes on heart failure outcomes, the potential of glycemic control in improving the outcome of diabetic patients with heart failure has not been fully examined. It is likely that optimal glycemic control might be able to reduce mortality and hospitalization in heart failure patients with diabetes, and should be considered as part of a comprehensive management strategy in such patients.

PATHOPHYSIOLOGY OF HEART FAILURE IN DIABETICS

The mechanisms of diabetes in leading to heart failure are not entirely clear. Recent studies have suggested several

specific cellular or metabolic pathways where diabetes may compromise myocardium leading to heart failure.

First, the coexistence of myocardial ischemia, hypertension, and a specific diabetic cardiomyopathy seems to independently and cooperatively contribute to biochemical, anatomic, and functional alterations in cardiac cells and tissues that impair cardiac function (8). Diabetic cardiomyopathy, characterized by myocellular hypertrophy and myocardial fibrosis, contributes to the high incidence and poor prognosis of heart failure. Diabetic cardiomyopathy has been found to be associated with depressed mechanical function, electrophysiological abnormalities, defects in subcellular organelles, and receptor downregulation because of chronically elevated catecholamine levels (8). Hypertension is a common complication of diabetes and is associated with further damage to the myocardial contraction and ventricular function through increased myocardial fibrosis and development of coronary artery disease or myocardial ischemia (8).

Diabetic heart failure patients may have a higher risk of coronary plaque rupture and thrombosis. Recurrent myocardial infarction is a major cause of death in patients with ischemic heart failure; in addition, non-fatal myocardial infarction may further deteriorate left ventricular function in patients with ischemic heart failure.

Second, autonomic dysfunction commonly seen in patients with diabetes may contribute the development of

cardiomyopathy and heart failure. Renin-angiotensin system and sympathetic nervous system are two important compensatory mechanisms to maintain a relatively stable hemodynamics in the early stage of ventricular dysfunction. Although activation of the adrenergic and renin-angiotensin systems is quite effective for short-term compensation, there are long-term adverse consequences of chronic activation of these systems that may override any initial benefit. The harmful effect of long-term activation of these systems include progressive loss of cardiac myocytes, cellular hypertrophy, depletion of high-energy phosphate reserves, and norepinephrine toxicity may, all of which may lead to further decreases of ventricular function (9).

DIABETES AS A RISK PREDICTOR FOR HEART FAILURE

The prognostic importance of diabetes in patients with heart failure was demonstrated in the well-known Framingham publications (3). Retrospective analyses of the SOLVD trials have suggested that diabetic status may be useful as a prognostic indicator in HF patients (10). In this study, both all-cause mortality and cardiovascular mortality at a mean follow-up of 3 years were significantly higher in diabetic than in non-diabetic heart failure patients (10). Recent evidence suggests that the effect of diabetes mellitus on survival is more pertinent to heart failure of ischemic origin; diabetes mellitus is associated with an increased risk for all-cause mortality in patients with ischemic heart failure, but not in patients with non-ischemic heart failure (11). The effect of etiology was also recently studied in patients with advanced heart failure enrolled in the BEST trial which showed that diabetes conferred an increased risk for adverse cardiovascular events in patients with ischemic etiology (13). In contrast, in patients with nonischemic etiology, diabetes was not a predictor for all-cause death or cardiovascular death (12). Diabetics with heart failure of nonischemic etiology may have opposite prognostic implications in heart failure with ischemic etiology. In a relatively large cohort of study, diabetes was actually associated with decreased cardiovascular mortality (4). The reasons for the reduced mortality in the non-ischemic heart failure are unknown and the results should be interpreted with caution.

SUMMARY

Although there are strong evidence for increased cardiovascular mortality in patients with heart failure and diabetes, there is little prospective study on the benefits of aggressive diabetes control in such patients. Patients with diabetes have an increased level of myocardial free fatty

acids that have been shown to depress myocardial contractility and increase myocardial oxygen consumption (13). In a recent study that included 63% of cardiac surgery patients with and without diabetes, lowering glucose to normoglycaemia allowed a 32% reduction of mortality from multi-organ failure (14). In another study on patients with diabetes mellitus and acute myocardial infarction, standard treatment plus insulin-glucose infusion for at least 24 hours followed by multidose insulin treatment improved long term survival, and the effect seen at one year continues for at least 3.5 years, with an absolute reduction in mortality of 11% (15).

It is likely that optimal glycemic control with insulin or other hypoglycemic drugs plays an important role in improving the clinical outcomes of heart failure. Optimal glycemic control offers benefits in cardiac metabolism and performance in heart failure patients by decreasing myocardial free fatty acid oxidation and increasing glucose utilization, and may be particularly useful in heart failure patients with ischemic cardiomyopathy.

ACKNOWLEDGEMENT

This work is supported by a research grant from Diabetes Australia Research Trust (DART).

References

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. *JAMA* 1979; 241:2035-2038.
2. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. *Diabetes Care* 2001; 24:1614-1619.
3. Abbott RD, Donahue RP, Kannel WB et al. The impact of diabetes on survival following myocardial infarction in men vs. women. The Framingham Study. *JAMA* 1988; 260:3456-3460.
4. De Groote P, Lamblin N, Mouquet F et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. *Eur Heart J* 2004; 25:656-662.
5. Burger AJ, Tsao L, Aronson D. Prognostic impact of diabetes mellitus in patients with acute decompensated heart failure. *Am J Cardiol* 2005; 95:1117-1119.
6. Varela-Roman A, Grigorian Shamagian L, Barge Caballero E, Mazon Ramos P, Rigueiro Veloso P, Gonzalez-Juanatey JR. Influence of diabetes on the survival of patients hospitalized with heart failure: a 12-year study. *Eur J Heart Fail* 2005; 7:859-64.
7. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. *Am J Med* 2006; 19:591-599.
8. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. *Diabetes Care* 2003; 26:2433-41.
9. Eichhorn EJ, Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. *Circulation* 1996;

94:2285-2296.

10. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. *Am J Cardiol* 1996; 77:1017-1020.

11. Dries DL, Sweitzer NK, Drazner MH et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. *J Am Coll Cardiol* 2001; 38:421-428.

12. Domanski M, Krause-Steinrauf H, Deedwania P et al., BEST Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. *J Am Coll Cardiol* 2003; 42:914-22.

13. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P,

Waldenstrom A, Wedel H, Welin L: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. *J Am Coll Cardiol* 1995; 26:57-65.

14. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001; 345:1359-1367.

15. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. *BMJ* 1997; 314:1512-1515.

Author Information

Lexin Wang, MD, PhD, FCSANZ

Professor of Clinical Pharmacology, School of Biomedical Sciences, Charles Sturt University

Norelle Owen, RN

Cardiovascular Research Assistant, School of Biomedical Sciences, Charles Sturt University